TrialJMIR mHealth and uHealth2021

WeChat as a Platform for Baduanjin Intervention in Patients With Stable Chronic Obstructive Pulmonary Disease in China: Retrospective Randomized Controlled Trial.

Junjie Bi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.